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Asthma is considered an heterogeneous disease, requiring multiple biomarkers for diagnosis and management.
Fractional exhaled nitric oxide in exhaled breath (FeNO) was the first useful non-invasive marker of airway
inflammation in asthma and still is the most widely used. The non-invasive nature and the relatively easy use of
FeNO technique make it an interesting tool to monitor airway inflammation and rationalize corticosteroid therapy
in asthmatic patients, together with the traditional clinical tools (history, physical examination and lung function
tests), even if some controversies have been published regarding the use of FeNO to support the management of
asthma in children. The problem of multiple confounding factors and overlap between healthy and asthmatic
populations preclude the routine application of FeNO reference values in clinical practice and suggest that it would
be better to consider an individual “best”, taking into account the context in which the measurement is obtained
and the clinical history of the patient. Besides, there is still disagreement about the role of FeNO as a marker of
asthma control, due to the complexity of balance among the different items involved in its determination and the
lack of homogeneity in the population groups studied in the few studies conducted so far. Heterogeneity of
problematic severe asthma greatly limits utility of FeNO alone as a biomarker of inflammation to optimize the
disease management on an individual basis. None of the studies conducted so far demonstrated that the use of
FeNO was better than current asthma guidelines in controlling asthma exacerbations. In summary, there is a large
variation in FeNO levels between individuals, which may reflect the natural heterogeneity in baseline epithelial nitric
oxide synthase activity and/or the contribution of other noneosinophilic factors to epithelial nitric oxide synthase
activity. FeNO is a promising biomarker, but at present some limits are highlighted. We would recommend that
further research can be carried out by organizing studies aimed to obtain reliable reference values of FeNO and in
order to better interpret FeNO measurements in clinical settings, taking also into account the influence of genetic
and environmental factors.Review
Introduction
Asthma is a chronic inflammatory disorder of the airways,
in which underlying structural and functional changes
occur [1]. The increased knowledge of the deep interplay
between the pathophysiological pathways of chronic air-
way inflammation and remodelling in asthma has led to
consider asthma an heterogeneous disease, requiring in-
formation on multiple biomarkers for diagnosis and man-
agement [2]. Fractional exhaled nitric oxide in exhaled* Correspondence: stefania.lagrutta@ibim.cnr.it
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reproduction in any medium, provided the orbreath (FeNO) was the first useful non-invasive marker of
airway inflammation in asthma and still it is the most
widely used [2,3].
The non-invasive nature and the relatively easy use of
FeNO technique make it an interesting tool to monitor
airway inflammation and rationalize corticosteroid ther-
apy in asthmatic patients, together with the traditional
clinical tools (history, physical examination and lung
function tests) [4], even if some controversies have been
published regarding the use of FeNO to support the
management of asthma in children [5].
FeNO levels correlate with eosinophilic counts in in-
duced sputum or bronchoalveolar lavage fluid as well as
with eosinophil infiltration of the airways and peripheral
eosinophilia, mainly in atopic subjects [3,6]. Correlations
were also found with total IgE, serum eosinophil cationicl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tests, whereas there are only weak correlations with spiro-
metric outcomes and clinical measures of asthma [3,7].
Nevertheless, more recent findings about the positive
cross-correlation of daily fluctuations in FeNO values
with symptom scores may open a new vision of this bio-
marker use in childhood asthma [8]. Moreover, it has
been recently found a linear association between FeNO
and bronchial responsiveness in children with and without
asthmatic symptoms suggesting the continuity of bron-
chial inflammation from health to disease and the impor-
tance of this measurement together with other clinical
end points, such as lung function, symptoms and symp-
tom history [9,10].
The aim of this review is to elucidate what could be
the role of FeNO in the assessment of asthma severity
and control. We will also look at the perspectives of
considering the relation between FeNO measurement
and various clinical phenotypes of pediatric asthma.
FeNO reference values: an unresolved issue
Normal values of FeNO and feasibility in children have
been already assessed.
FeNO levels in healthy children are below 15 to 25 ppb,
depending on several non-disease-related factors, such as:
age, gender, height, ethnicity, genetics, self-reported atopy,
allergic sensitization, total IgE, time of testing, infections,
a nitrate rich diet, exercise, smoking, ambient nitric oxide,FeNO
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DETERMINANTS
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Figure 1 Disease and non-disease-related factors influencing FeNO. F
such as environmental determinants and clinical characteristics, and diseas
factors have to be considered in clinical setting, because they may influenctime of the day and season and environmental pollution
[3,11-14] (Figure 1). All these confounding factors have to
be considered when evaluating FeNO levels in clinical set-
ting, because they may influence FeNO values and, conse-
quently, patient’s management [6,15].
Studies aimed to define the right cut-point to diagnose
asthma using FeNO pointed to a range from 20 to 25 ppb,
even if these values may range from 22 to 44 ppb in sub-
jects with well-controlled asthma. This suggests that there
is an overlap between mean FeNO levels in healthy and
asthmatic people [4].
There is also evidence that atopy, mainly allergic sensi-
tization to perennial allergens, is per se able to significantly
affect FeNO levels playing an important role in elevating
nitric oxide (NO) production, even in asymptomatic sub-
jects, probably through long-lasting inflammatory stimuli
in the airways. In our experience, a significant relation be-
tween FeNO values and number of positive skin tests was
found, with the highest FeNO levels observed in atopic
children with doctor-diagnosed asthma. This suggests that
atopy and asthma may be the most consistent predictor of
high FeNO levels [7].
The problem of multiple confounding factors and over-
lap between healthy and asthmatic populations preclude
the routine application of FeNO reference values in clin-
ical practice and suggests that it would be better to con-
sider an individual “best”, taking into account the context
in which the measurement is obtained and the clinicalATOPY
INDIVIDUAL
CHARACTERISTICS
eNO levels in children depend both on non-disease-related factors,
e-related factors, such as asthma and atopy. All these confounding
e FeNO values and, consequently, patient’s management.
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reproducible in an individual, so it might be more success-
ful to use personalized cut-off values for each subject, ra-
ther than using a single cut-off value for all patients [2].
Asthma control and FeNO
The goal of asthma treatment is achieving control of symp-
toms and airway inflammation and maintaining pulmonary
function [9].
The need for a reliable method to assess the level of
asthma control is related to the recent update of inter-
national guidelines, suggesting that tailored asthma treat-
ment to the level of disease control, rather than severity,
should be performed [16].
Although the burden of airway inflammation in the
clinical phenotypes is still under debate, inflammation has
an important pathophysiological role for the management
of chronic respiratory diseases and is relevant in guiding
pharmacological therapy [17,18]. In this context, FeNO
might be an useful tool in evaluating asthma control.
FeNO values are related to several markers of asthma
control, such as night time symptoms, beta-agonist use,
and bronchodilator reversibility [19], as well as to the
use of oral or inhaled steroid treatment [20]. In addition,
previous studies showed that FeNO is raised in asthmatic
children, especially when asthma is uncontrolled and during
exacerbations [15]. Hence, FeNO may provide useful infor-
mation about airway inflammation as a complementary toolTable 1 Asthma control and FeNO
Author Age range (years) Subjects (number)
Covar RA, JPediatr 2003 5–12 92 with mild to
moderate asthma
Smith AD, J Allergy
ClinImmunol 2009
12–75 73 with chronic asthma
in treatment with ICS
Fritsch M, Pediatr
Pulmonol 2006
6–18 47 with mild to moderate
persistent asthma
Waibel V, Pediatr
Pulmonol 2012
12 (mean age) 107 with a diagnosis of as
Cabral ALB, AnnalsAllergy
Asthma Immunol 2009
7–14 32 with moderate-to-sev
asthma
Green RJ, Chest 2013 4–11 71 with atopic asthmato lung function tests, in order to obtain a better control of
asthma symptoms and an optimal rationalization of anti-
inflammatory therapy.
Conversely, recent studies found that a treatment aimed
at lowering FeNO levels in asthmatic children cannot im-
prove clinical markers of asthma control [21], and incon-
sistent data were found about the correlations between
FeNO and Asthma Control Test scores, both in adults and
in children [9]. So, there is generally no evidence that the
measurement of FeNO adds value as a predictor of asthma
control compared to conventional tests of lung function or
that regular measurement of FeNO leads to important
benefits in adjusting the dose of steroid therapy, thus this
value alone cannot be recommended to assess asthma
control [4]. However, it should be noted that the disagree-
ment between FeNO and lung function is probably due to
the lack of homogeneity of the different population groups
of children studied, with different inclusion criteria, con-
cerning the severity of asthma, the use of inhaled cortico-
steroid therapy and dosage, presence of atopy, as well as
different definitions of control used [5,22] (Table 1).
In summary, there is still disagreement about the role
of FeNO as a marker of asthma control, due to the com-
plexity of balance among the different items involved in
its determination and the lack of homogeneity in the
population groups studied in the few studies conducted
so far (Figure 2). Because of the complex nature of the
disease, asthma control reasonably needs more than oneCorrelation Direction of effect
. degree of bronchial
hyperresponsiveness
Yes
. bronchodilator reversibility
. allergen skin prick tests
. serum IgE
. eosinophil count
. nocturnal symptoms, β-agonist
use at least once weekly.
. asthma control (changes in
symptoms, bronchodilator use,
diurnal peak flows, spirometry)
No
. dose of ICS (p < 0.002) Yes
. b-agonist use 2 weeks prior
to a visit (p<0.05)
. asthma symptoms (p < 0.0001)
. bronchial hyperresponsiveness (p = 0.02)
thma . C-ACT No
ere . risk for exacerbations No
. spirometry No
. ACT
Atopy
•Eos count
•IgE total
Moderate Exacerbations
Frequency of Severe Exacerbations
Asthma symptoms 
Nocturnal symptoms 
CONTROL SEVERITY
Bronchial  
hyperresponsiveness
Markers of 
airway 
inflammation
induced sputum 
Severe Exacerbations
Skin Prick Test
Rescue Medication Use
•Diurnal Peak Flow 
•Spirometry
•ACT
Risk of Exacerbations
(-)
(-)
(-)
(-)
Figure 2 Role of FeNO as a marker of asthma control and severity. The continuous lines indicate the evidence of relationship between
FeNO and several markers of asthma controls; the dashed lines indicate no evidence.
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objective testing are required [5].
Severity of asthma and FeNO
Although the majority of children with asthma respond
well to standard therapy, a significant proportion still have
problematic, severe disease that is not controlled with
conventional management.
The utility of FeNO for monitoring children with
moderate-to-severe asthma is uncertain. In fact, studies
aimed to evaluate FeNO usefulness as a predictor of asth-
ma exacerbations show conflicting results. Moreover, there
is not consensus yet about the optimal FeNO cut-point
level to define high risk of exacerbation. A recent study by
Cabral et al. showed no benefits in tapering ICS doses in
atopic children by monitoring FeNO levels, suggesting that
this tool has a limited value as a predictor of asthma exac-
erbations [22]. Conversely, some data reported that FeNO
might be helpful in predicting and preventing exacerba-
tions. Gagliardo et al. found a significant correlation be-
tween FeNO levels and other markers of inflammation,
such as sputum eosinophilia and IL-8, and the number of
severe exacerbations in asthmatic children [23]. More re-
cently, Van der Valk et al. studied longitudinal daily FeNO
measurements in relation to exacerbations in atopic asth-
matic children founding changes in FeNO prior to moder-
ate, but not severe, exacerbations. The Authors speculated
that moderate exacerbations were probably preceded by
increased eosinophilic airway inflammation and that the
level of cross-correlation between FeNO levels and symp-
toms could identify children at risk for exacerbations.
However the study sample size was small and thetherapeutic intervention with inhaled corticosteroid (ICS)
could have modified the association between FeNO and
exacerbations [24] (Table 2).
Some factors such as genetic variation in FeNO levels,
increased diffusion of NO in asthmatic airways, the associ-
ation of FeNO with atopy and airway hyperresponsiveness,
may have weight on child’s asthma difficult to control
leading to higher FeNO levels [25]. Moreover, it has been
emphasized that many children may have factors apart
from the underlying severity of asthma that contribute to
their severe disease, including comorbidities, socioeco-
nomic problems, adverse environmental exposures (such
as tobacco smoke, relevant allergens and other harmful
factors), psychological problems and poor adherence to
treatment.
Hence, heterogeneity of problematic severe asthma
greatly limits utility of FeNO alone as a biomarker of in-
flammation to optimize the disease management on an
individual basis.
Management of asthma and FeNO
There is a strong interest to use FeNO as a guide for
asthma treatment, based on the premise that FeNO re-
flects airway inflammation. In fact, in some studies FeNO
is validated as a useful tool both in diagnosing and man-
aging patients with atopic asthma [26].
Sensitivity and specificity of FeNO measurements were
showed to be acceptable to discriminate asthma from other
non-asthmatic conditions in previous clinical studies. How-
ever, it should be remembered that normal FeNO levels
do not exclude the diagnosis of asthma, especially in non
atopic subjects. On the other hand, elevated values, while
Table 2 Asthma severity and FeNO
Author Age range (years) Subjects (number) Correlation Direction of effect
Gagliardo R,
PediatrAllergyImmunol 2009
6-14 35 with asthma . eosinophilia in induced sputum Yes
. IL-8 in induced sputum
. allergen skin prick tests
. number of severe exacerbations
Van der Valk RJ, Allergy 2012 10.9 (mean age) 72 with asthma . moderate exacerbations Yes
Franklin PJ, Thorax 2003 11.5 (mean age) 155 enrolled from an
unselected population
. atopy (p < 0.001) Yes
. level of AR (p = 0.005)
. blood eosinophil count (p = 0.007)
. bronchial hyperresponsiveness
(p = 0.02)
AR airway reactivity.
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and management of the disease, mainly in clinically con-
trolled patients [27]. Thus, the question is whether to treat
patients according to the clinical control and lung function
tests or according to the FeNO values, which may suggest a
latent inflammation [26].
It has been suggested that FeNO may be more ap-
propriate for tapering, rather than for stepping up anti-
inflammatory treatment and could be used mainly as an
indicator of the patient’s compliance with the prescribed
therapy [3]. In addition, the relatively rapid change of
FeNO levels after steroid treatment suggests its utility in
monitoring adherence to and response to therapy, being
an indicator of patient compliance with the prescribed
therapy [2,4].
Nevertheless, two meta-analysis of paediatric studies
showed that FeNO monitoring lead to increased use of ICS,
without significant influence on lung function outcomes
(FEV1) compared to conventional management [28,29]. In
fact, while two studies have failed to observe any improve-
ment in asthma control compared with the use of standard
asthma guidelines, even using a daily FeNO monitoring
[30,31], other two studies showed an increased ICS dose in
FeNO follow up group compared to conventional follow up
group with no changes in asthma control [21]. In summary,
none of these studies was able to demonstrate that the use
of FeNO was better than current asthma guidelines in con-
trolling asthma exacerbations. Moreover, the data suggest
that using FeNO to tailor the dose of ICS cannot be rec-
ommended in routine clinical practice, because of the dan-
ger of excessive doses without significant changes in clinical
outcomes. High FeNO levels may be caused by non-disease
related factors that clinicians should be aware of in asthma
management. To date, a guideline-based approach still re-
mains essential [28].
In 2011, the American Thoracic Society (ATS) guide-
lines suggested that decision cut-points rather than refer-
ence values have to be used in FeNO levels interpretation.
Specifically, the guidelines stated FeNO values < 25 ppb(20 ppb in children <12 years) a low likelihood of eosino-
philic inflammation and corticosteroid response, while
FeNO values >50 ppb (35 ppb in children <12 years) indi-
cate otherwise [4]. Similarly, a recent work by See et al.
showed that in the US general population there is a large
variation of normal FeNO levels; values >39 ppb in sub-
jects aged 12 to 80 years (36 ppb in children aged 6–11
years) indicated abnormality and a high risk of airway in-
flammation [32]. These data support the ATS guideline
recommendations that clinical interpretation of FeNO
should depend on thresholds rather than reference values.
However, further studies are needed to get more reliable
FeNO cut-off values for treatment decisions [28].
Asthma phenotypes and FeNO
Asthma is a complex disease characterized by different
underlying pathophysiologies. This biological heterogeneity
translates into clinical practice in different phenotypes of
the disease. Clinical phenotypes of asthma are subgrouped
according to characteristics such as symptoms, inflamma-
tion, lung function and treatment response. Recently, much
effort has been done to link this features with molecular
pathways defining the new concept of ‘endotype’. This term
refers to the patient’s characterization including natural
history, genetics and clinical features, arising from an
underlying specific pathobiology associated with reliable
biomarkers and a predictable response to therapy. The
identification of this subgroup of patients is fundamental to
design a targeted treatment strategy and improve treatment
response, achieving the control of the disease. Originally
asthma was classified in extrinsic (allergic) and intrinsic
(non allergic) asthma. Most recently other asthma pheno-
types have been identified, including early onset allergic
asthma, exercise induced asthma and non Th2-associated
asthma (neutrophilic asthma, obesity-related asthma and
smoking asthma) [33].
Elevated levels of FeNO are reported as a biomarker for
an allergic asthma phenotype. Several studies highlighted
the relationship between FeNO and eosinophilic airway
Ferrante et al. Multidisciplinary Respiratory Medicine 2013, 8:50 Page 6 of 8
http://www.mrmjournal.com/content/8/1/50inflammation [4]. Moreover, various studies demonstrated
that FeNO is increased in atopic individuals with and with-
out asthma, suggesting that atopy and asthma could be co-
factors in determining elevated FeNO levels [7,34,35].
Recently, it has been shown that baseline FeNO levels are
high in children with exercise-induced bronchoconstriction
and correlate with the degree of post-exercise broncho-
constriction, suggesting that FeNO may be a predictor of
airway hyperresponsiveness to exercise, particularly in asth-
matic children sensitive to indoor allergens [36].
Many studies evaluated the relationship between FeNO
and obesity in asthmatic patients showing no significant
relationship between FeNO and Body Mass Index in
asthmatic subjects, and suggesting that childhood obesity
is not associated with increased airway inflammation
[7,11,37,38].
Finally, there is evidence that active smoking and cigarette
smoke exposure are correlated with lower FeNO levels both
in adults and in children with asthma. This could be due to
different mechanisms according to the type of exposure.
Acute exposure induces a marked but transient decrease in
FeNO levels related to a negative feedback of inducible NO
synthase (iNOS) activity, since tobacco smoke contains high
concentrations of nitric oxide. Daily smoke exposure is
probably associated with a progressive negative feedback
leading to the inhibition of iNOS gene expression [6].
Despite this evidence, a recent work by Mahut et al.
found that FeNO is not associated with a clinically rele-
vant phenotype in asthmatic children, in accordance with
other trials failing to demonstrate the clinical usefulness
of this measure for asthma control [39].
In summary, there is a large variation in FeNO levels
among individuals, which may reflect the natural hetero-
geneity in baseline epithelial nitric oxide synthase activity
and/or the contribution of other noneosinophilic factors
to epithelial nitric oxide synthase activity. Interindividual
variation in FeNO combined with the inherent heterogen-
eity of asthma increases the background noise, which ren-
ders FeNO a relatively insensitive tool for guiding therapy
in all asthmatics [40]. However, considering the relation-
ship between eosinophilicinflammation and steroid re-
sponsiveness in airway disease, it is plausible to use FeNO
as an indicator of treatment response. Since not all asth-
matic patients respond to ICS therapy, FeNO might help
to identify patients with asthma-like symptoms who could
benefit or not from corticosteroid treatment [4].
Conclusions
The development of a diagnostic tool for asthma at an
early age, based on non-invasive inflammatory biomarkers
in exhaled breath should be a milestone for the good
asthma diagnosis and management in childhood. In this
context, the data of literature indicate that the assessment
of non-invasive markers, such as FeNO in asthmatics,would be an additional field for the best detection of in-
flammatory components.
Actually, FeNO assessment shows some advantages, in-
cluding the good correlation with symptoms of asthma, use
of beta-agonist and risk of exacerbations. Since FeNO as a
marker of eosinophilic airway inflammation has the poten-
tial to serve as an indicator of the adequacy of ICS-anti-
inflammatory treatment, it could be successfully used to
monitor the response to ICS-therapy, improving the tai-
lored steroid therapy in asthmatic children for a better con-
trol of the disease [15]. Lastly, FeNO assessment might be
useful to identify patients with uncontrolled diseases and to
verify the usefulness of new therapeutic approaches [41].
Considering the prevalence of childhood asthma and its
associated burden, it is mandatory to obtain an optimal
control of the disease, improving outcomes for patients as
well as reducing costs attributable to poorly controlled pa-
tients [42]. Currently, an economic evaluation of FeNO
measurement is scanty, even if Berg and coworkers showed
that using FeNO in asthma diagnosis and management in
Germany is less costly than management based on standard
guidelines; in fact the FeNO assessment cost was offset by
the reduction of exacerbations and hospitalizations, due
to a better control of the disease, especially in mild to
severe adult patients [43]. Furthermore, a study conducted
in the United Kingdom showed similar findings in adults,
suggesting that FeNO measurement can be considered a
cost-effective alternative to standard tests for both asthma
diagnosis and management as well as an useful tool in pro-
viding a more complete picture of airway status [44]. On
the contrary, the results from clinical trial in asthmatic chil-
dren show that FeNO assessment in asthma management
is more expensive and does not have predictive value [45].
Although FeNO is a promising biomarker, at present
some limits are highlighted. Essentially, some disagree-
ment exists about the appropriate cut-off points of normal
FeNO level, which is crucial to guide the appropriate clin-
ical response. As previously discussed, its utility is lost
when it is applied to all asthmatics because of the under-
lying heterogeneity of the phenotypes.
In practice, before considering biomarkers for a clinical
use, we must appreciate that asthma is a heterogeneous
disease and a panel of biomarkers is needed to indicate
the various and different underlying disease pathologies.
Regardless of the complexity or completeness of a future
panel of asthma biomarkers, it is highly unlikely that they
will completely replace pulmonary function testing in clin-
ical practice. Indeed, biomarker testing will be designed to
complement rather than replace existing methods of clin-
ical diagnosis and disease monitoring.
Towards future research
In light of the reviewed evidence, we would recommend
that further research can be carried out by organizing
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taking also in account the influence of genetic and envi-
ronmental factors. Moreover, further research is required
to better interpret FeNO measurements in clinical set-
tings, as FeNO could be useful in understanding asthmatic
patients in whom more than one factor contributes to re-
spiratory symptoms (obesity, anxiety, environmental ex-
posure). Finally, more studies are needed to understand
the role of FeNO in monitoring response to therapy [4].
Therefore, a periodically update of specific guidelines re-
lating to this rapidly evolving field of research is strongly
desirable.
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